Form 4: Precigen CEO Helen Sabzevari Granted 500,000 Restricted Stock Units

Precigen, Inc. CEO and Director Helen Sabzevari was granted 500,000 restricted stock units, which will vest over approximately three years starting May 23, 2026.

Summary

• Helen Sabzevari, the President and CEO, and a Director of Precigen, Inc. (PGEN), was granted 500,000 Restricted Stock Units (RSUs) on June 26, 2025.
• Each RSU represents a contingent right to receive one share of Precigen common stock.
• The RSUs are scheduled to vest 50% on May 23, 2026, with the remaining portion vesting in equal monthly installments over the subsequent three years.
• Following this transaction, Ms. Sabzevari beneficially owns 500,000 RSUs.
• The filing was made pursuant to Section 16(a) of the Securities Exchange Act of 1934 and indicates the transaction was made pursuant to a Rule 10b5-1(c) plan.

Sentiment

Score: 7

Explanation: The grant of a significant number of Restricted Stock Units to the CEO is a positive signal for long-term alignment of management's interests with shareholder value, as it incentivizes sustained performance. It reflects a standard, positive corporate governance practice.

Positives

• The grant of 500,000 Restricted Stock Units to the President and CEO aligns her long-term financial interests with those of the shareholders, incentivizing sustained company performance.
• The multi-year vesting schedule demonstrates a commitment to long-term retention of key leadership and encourages a focus on future value creation.

Negatives

• The RSUs do not confer immediate share ownership or voting rights until they vest, meaning the CEO does not yet have direct equity in these units.

Future Outlook

The document primarily details an executive compensation grant and does not provide forward-looking statements regarding the company's financial performance or strategic direction, beyond the vesting schedule for the granted units.

Industry Context

The grant of Restricted Stock Units to a top executive is a common practice in the biotechnology and pharmaceutical industries, serving as a key component of executive compensation packages designed to attract, retain, and incentivize leadership. This aligns with standard industry practices for long-term incentive plans.

Comparison to Industry Standards

• Restricted Stock Unit grants are a widely adopted form of executive compensation across various industries, including biotechnology, as they tie executive rewards directly to company performance and shareholder value over time.
• While the specific size of the grant (500,000 RSUs) would typically be benchmarked against grants to CEOs of similarly sized and stage-of-development companies within the biotech sector, this document does not provide the necessary comparative data for a detailed assessment against specific comparable companies or projects.

Related Party Transactions

• The document details an executive compensation grant of 500,000 Restricted Stock Units to Helen Sabzevari, the President and CEO, and a Director of Precigen, Inc. This is a transaction with a related party (an insider) as part of her compensation package.

Stakeholder Impact

• Shareholders: Potential for long-term value creation as the CEO's compensation is tied to the company's stock performance, aligning her interests with shareholder returns.
• Employees: May signal stability and confidence in leadership, potentially boosting morale and long-term strategic focus.

Next Steps

• Vesting of 50% of the granted Restricted Stock Units on May 23, 2026.
• Subsequent monthly vesting installments for the remaining RSUs over three years following May 23, 2026.

Key Dates

Keywords

Precigen, PGEN, Helen Sabzevari, Restricted Stock Units, RSU, Executive Compensation, Insider Transaction, SEC Form 4, Stock Grant